Taysha gene therapies continues to add significant gene therapy expertise to leadership team with the appointment of chief legal officer and chief people officer

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of timothy j. douros, j.d., as chief legal officer and corporate secretary and tracy m. porter, m.ed., sphr, as chief people officer. m
TSHA Ratings Summary
TSHA Quant Ranking